-transparent.png){kind=logo}
1. In order to characterize the physiological functions of the domain structure of secretory leukoprotease inhibitor (SLPI), the biological capacities of half-length SLPIs, (Ser1-Pro54)SLPI and (Asn55-Ala107)SLPI, were investigated and compared with those of full-length SLPI. 2. The activities of these inhibitors against several serine proteases were determined using synthetic chromogenic substrates. The inhibitory capacity of the C-terminal domain, (Asn55-Ala107)SLPI, was as strong as that of full-length SLPI against human neutrophil elastase (NE), cathepsin G and chymotrypsin. It possessed less trypsin inhibitory activity than intact SLPI. For the N-terminal domain of SLPI, (Ser1-Pro54)SLPI, no inhibitory activity could be detected against the serine proteases tested in this study. 3. The inhibitory activity of (Asn55-Ala107)SLPI against the proteolysis of the natural substrates elastin and collagen by NE was comparable with that of full-SLPI (elastin, IC50 = 907 +/- 31 nM for SLPI, 767 +/- 33 nM for (Asn55-Ala107)SLPI; collagen, IC50 = 862 +/- 36 nM for SLPI, 727 +/- 47 nM for (Asn55-Ala107)SLPI). 4. The binding affinities of full- and half-length SLPIs for heparin were measured by affinity column chromatography. Full-length SLPI showed high affinity for heparin while the binding capacities of both half-length SLPIs were lower. (Concentration of NaCl for elution, 0.45 M for SLPI, 0.24 M for (Ser1-Pro54)SLPI, 0.27 M for (Asn55-Ala107)SLPI). 5. The effects of full-SLPI and (Asn55-Ala107)SLPI on blood coagulation were measured using the activated partial thromboplastin time (APTT). Full-length SLPI prolonged clotting time dose dependently(1.25, 2.5 and 5.0 microM), whereas (Asn55-AlalO7)SLPI had no effect even at the highest concentration.6. In conclusion, the C-terminal domain of SLPI is a promising candidate for the treatment of inflammatory diseases in which participation of neutrophil proteases has been suggested.
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
May 1994,
Biochemistry,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
October 1997,
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
February 2014,
American journal of physiology. Lung cellular and molecular physiology,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
February 1996,
Nihon rinsho. Japanese journal of clinical medicine,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
December 1996,
Chest,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
August 2005,
Mammalian genome : official journal of the International Mammalian Genome Society,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
June 1991,
The Journal of clinical investigation,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
March 1993,
The American review of respiratory disease,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
January 2017,
PloS one,
K Masuda, and
T Kamimura, and
K Watanabe, and
T Suga, and
M Kanesaki, and
A Takeuchi, and
A Imaizumi, and
Y Suzuki
May 1995,
American journal of respiratory and critical care medicine,
